Translating molecular insights into clinical success: alkaloid-based therapies for leukemia
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03540-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Pouya Goleij und 8 weiteren Autor:innen. Beteiligte Einrichtung: USERN Office, Kermanshah University of Medical Sciences, Kermanshah, Iran. medgenetic.1991@gmail.com. Hauptthemen laut MEDLINE: Alkaloids, Leukemia, Antineoplastic Agents, Phytogenic, Antineoplastic Agents. Die Arbeit nennt 128 Literaturangaben.
Abstract (Originalsprache)
Alkaloids, a diverse class of naturally occurring compounds, have shown significant potential in the treatment of leukemia by targeting key molecular pathways and cellular mechanisms. This review discusses several potent alkaloids, such as homoharringtonine, chaetominine, matrine, and jerantinine B, which induce apoptosis, cell cycle arrest, and autophagy and inhibit signaling pathways including PI3K/Akt/mTOR, MAPK, and NF-κB. For instance, homoharringtonine induces apoptosis in acute myeloid leukemia (AML) cells via the SP1/TET1/5hmC/FLT3/MYC axis, while chaetominine enhances chemosensitivity by inhibiting the PI3K/Akt/Nrf2 pathway. In addition, targeting leukemia stem cells (LSCs) with alkaloids such as zalypsis offers promise due to its ability to induce apoptosis without significantly affecting normal hematopoietic stem cells. The modulation of the immune response, such as the inhibition of NF-κB activation by noscapine, further underscores the potential of alkaloids in overcoming treatment resistance. Various studies have demonstrated the efficacy of alkaloids across different leukemia types. For example, jerantinine B targets AML cells, while vincristine has shown success in lymphocytic leukemia. Clinical trials have also highlighted the benefits of alkaloids, including homoharringtonine, which achieved a 79.9% complete remission rate in AML patients. However, adverse effects such as neutropenia and hepatotoxicity necessitate careful management. Collectively, these findings emphasize the need for further research into alkaloid-based combination therapies to enhance efficacy and minimize toxicity, providing a promising avenue for innovative leukemia treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah, Iran. medgenetic.1991@gmail.com.
- PhytoPharmacology Interest Group (PPIG), Network (USERN), Universal Scientific Education and Research, Tehran, Iran. medgenetic.1991@gmail.com.
- Department of Genetics, Sana Institute of Higher Education, Sari, Iran. medgenetic.1991@gmail.com.
- PhytoPharmacology Interest Group (PPIG), Network (USERN), Universal Scientific Education and Research, Tehran, Iran.
- Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
- Medical Doctor, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Goleij, P., Tabari, M. A. K., Rezaee, A., Sanaye, P. M., Daglia, M., Alijanzadeh, D., Alsharif, K. F., Kumar, A. P., & Khan, H. (2025). Translating molecular insights into clinical success: alkaloid-based therapies for leukemia. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03540-7
Vancouver
Goleij P, Tabari MAK, Rezaee A, Sanaye PM, Daglia M, Alijanzadeh D, et al. Translating molecular insights into clinical success: alkaloid-based therapies for leukemia. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03540-7
BibTeX
@article{Goleij2025,
author = {Goleij, Pouya and Tabari, Mohammad Amin Khazeei and Rezaee, Aryan and Sanaye, Pantea Majma and Daglia, Maria and Alijanzadeh, Dorsa and Alsharif, Khalaf F and Kumar, Alan Prem and Khan, Haroon},
title = {Translating molecular insights into clinical success: alkaloid-based therapies for leukemia},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03540-7}
}
EUVIMED